Human anti-FGFR4 antibody

Patent metadata

Field	Value
Publication number	US-10358498-B2
Application number	US-201515503095-A
Country	US
Kind code	B2
Filing date	Aug 11, 2015
Priority date	Aug 11, 2014
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

First claim

The invention claimed is:

1. An antibody which is directed against an epitope between amino acids 119-248 of human FGFR4, SEQ ID NO: 70, or an antigen binding fragment thereof, said antibody comprising:
(i) a heavy chain comprising:
(a) a CDRH1 as shown in SEQ ID NO: 3,
(b) a CDRH2 as shown in SEQ ID NO: 8, and
(c) a CDRH3 as shown in SEQ ID NO: 15, and

a light chain comprising:
(d) a CDRL1 as shown in SEQ ID NO: 23,
(e) a CDRL2 as shown in SEQ ID NO: 25, and
(f) a CDRL3 as shown in SEQ ID NO: 30,

or
(ii) a heavy chain comprising:
(a) a CDRH1 as shown in SEQ ID NO: 3,
(b) a CDRH2 as shown in SEQ ID NO: 8, and
(c) a CDRH3 as shown in SEQ ID NO: 15, and

a light chain comprising:
(d) a CDRL1 as shown in SEQ ID NO: 68,
(e) a CDRL2 as shown in SEQ ID NO: 27, and
(f) a CDRL3 as shown in SEQ ID NO: 35.

2. The antibody of claim 1 comprising a heavy chain variable region as shown in SEQ ID NO: 54 and a light chain variable region as shown in SEQ ID NOs. 62 and 67, or heavy and light chain variable regions differing in one or two amino acids from those shown in SEQ ID NOs. 54, 62 and 67.

3. The antibody of claim 1 , which is a Fab fragment, a Fab′ fragment, a F(ab′), fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

4. The antibody of claim 1 , which is of the IgG1-, IgG2-, IgG3- or IgG4-type.

5. A conjugate comprising an antibody of claim 1 , wherein the antibody is coupled to a labeling group or to an effector group.

6. A fusion protein comprising an antibody of claim 1 fused to IL-2.

7. A process of manufacturing an antibody of claim 1 , a conjugate thereof coupled to a labeling group or to an effector group, or a fusion protein thereof fused to IL-2, comprising the step of obtaining said antibody, antibody conjugate or fusion protein from a host.

8. A pharmaceutical composition comprising the antibody of claim 1 , a conjugate thereof coupled to a labeling group or to an effector group, or a fusion protein thereof fused to IL-2.

9. A kit comprising the antibody of claim 1 , a conjugate thereof coupled to a labeling group or to an effector group, or a fusion protein thereof fused to IL-2.

10. The antibody of claim 1 , comprising a heavy chain variable region as shown in SEQ ID NO. 54 and a light chain variable region according to SEQ ID NO. 62, or heavy and light chain variable regions differing in one or two amino acids from those shown in SEQ ID NO. 54 and 62.

Assignees

• Daiichi Sankyo Europe Gmbh
• Daiichi Sankyo Co Ltd

Inventors

• Abraham Reimar
• Fukuchi Keisuke
• Lange Tanja
• Bange Johannes
• Watanabe Ichiro
• Hayashi Shinko
• Ohtsuka Toshiaki

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title